Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

* Posters Showcase Early-Stage Clinical and Preclinical Pipeline. * Focus on ATG-037, ATG-018, A...

2022-03-09 20:00 2819

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed an...

2022-03-09 19:08 2520

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-03-02 08:47 2814

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2022-02-07 08:30 2871

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2022-01-05 12:50 3229

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

SHANGHAI and HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2021-12-30 09:51 3471

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-20 11:01 3654

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-20 10:56 2605

Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Antengene Corporation Limited (the "Company" ...

2021-12-17 22:27 5174

Antengene and XtalPi Announce AI-Driven R&D Collaboration

SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2021-12-16 16:30 3105

Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting

SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-12-14 18:00 2660

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

* ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor * C...

2021-12-13 08:30 2806

Antengene Included in the MSCI Global Small Cap Indexes - MSCI China Index Constituent Stocks

SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-11-26 11:34 4011

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights -...

2021-11-19 13:00 3456

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

SHANGHAI and Hong Kong, Nov. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-11-19 08:30 2810

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in chec...

2021-11-15 08:25 2545

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-09 16:30 2931

Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma

SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-02 08:30 3246

Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

SHANGHAI and HONG KONG, Nov. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-11-01 08:40 3284

Antengene to Host its First R&D Days on November 16 and November 18, 2021

* Virtual Event (in English) on November 16 * On Site Event with Live Webcast (in Mandarin) on N...

2021-10-25 20:00 3019